---
title: "Maxim Group Sticks to Its Buy Rating for Daxor (DXR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278233975.md"
description: "Maxim Group has maintained its Buy rating for Daxor (DXR) and set a price target of $22.00, while the stock closed at $11.38. The overall analyst consensus for Daxor is a Moderate Buy with an average price target of $23.00, indicating a potential upside of 102.20%. Lake Street also reiterated a Buy rating with the same price target of $23.00 in a report from March 5."
datetime: "2026-03-07T21:15:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278233975.md)
  - [en](https://longbridge.com/en/news/278233975.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278233975.md)
generator: "portal-rs"
---

# Maxim Group Sticks to Its Buy Rating for Daxor (DXR)

Maxim Group analyst reiterated a Buy rating on Daxor yesterday and set a price target of $22.00. The company’s shares closed yesterday at $11.38.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Daxor with a $23.00 average price target, representing a 102.20% upside. In a report released on March 5, Lake Street also reiterated a Buy rating on the stock with a $23.00 price target.

### Related Stocks

- [DXR.US](https://longbridge.com/en/quote/DXR.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Daxor wins US patent for remote blood volume monitoring technology](https://longbridge.com/en/news/297649081.md)
- [The Biggest Takeaway From ISRG Earnings](https://longbridge.com/en/news/283844761.md)
- [What's Going On With Intuitive Surgical Stock Wednesday?](https://longbridge.com/en/news/283661057.md)
- [03:17 ET3Shape Receives FDA 510(k) Clearance for 3Shape Dx Software](https://longbridge.com/en/news/284331015.md)
- [Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings](https://longbridge.com/en/news/283839392.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**